医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Milestone in Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb

2015年06月11日 PM03:38
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today the achievement of a milestone in one of the discovery programs in its alliance with US-based Bristol-Myers Squibb (NYSE:BMY). The milestone is the decision by Bristol-Myers Squibb to designate a Collaboration Compound as a candidate for exploratory clinical development, indicating that the compound has met certain pre-defined criteria and is now suitable for exploratory clinical development. The compound will now proceed to IND-enabling studies. Achievement of this milestone entitles PeptiDream to receive an undisclosed payment specified in the research collaboration and license agreement between PeptiDream and Bristol-Myers Squibb initiated October 15, 2010 and extended on October 15, 2012.

[Comments from Kiichi Kubota, President & CEO of PeptiDream Inc]

“We are very excited about the acceptance of a Collaboration Compound as a candidate for clinical development by Bristol-Myers Squibb. This is the first compound identified in the discovery collaboration to enter IND-enabling studies for Bristol-Myers Squibb and we look forward to its transition to clinical investigation. This decision by Bristol-Myers Squibb represents a key validation of PeptiDream’s peptide discovery platform and its ability to identify compounds that can be optimized for clinical studies. ”

About PeptiDream Inc.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Merck, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150610006494/en/

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.